Testicular Cancer (Germ Cell Tumors)

Why miR-371a-3p is the Primary Liquid Biopsy Biomarker

• Superior sensitivity: 88-98% for active disease vs ~50% for AFP/β-hCG/LDH
• Excellent specificity: 92-100% minimizes false positives
• Pan-histologic detection: Positive in seminomas, embryonal carcinoma, and other marker-negative tumors
• Early relapse detection: Detects recurrence earlier than conventional imaging
• Treatment monitoring: Rapid normalization with effective therapy

Clinical Applications of miR-371a-3p

• Diagnosis: Superior detection across all histologic subtypes, particularly valuable for seminomas
• Treatment monitoring: Rapid assessment of chemotherapy response; levels decline with effective therapy
• Post-treatment surveillance: Earlier detection of relapse compared to imaging modalities
• Marker-negative tumors: Provides biomarker monitoring where conventional markers fail (seminomas, pure embryonal carcinoma)
• Clinical decision-making: May reduce need for surveillance imaging in marker-negative patients

Regulatory and Clinical Milestones (2025-2026)

• FDA Breakthrough Device Designation (March 2025): The FDA granted mir|detect (German company) a Breakthrough Device Designation for its commercial miR-371a-3p assay, already marketed in Europe. This accelerates US regulatory review for clinical adoption.
• 10-Fold Recurrence Risk (ASCO GU 2026): A prospective study of 196 men demonstrated that detectable miR-371a-3p after orchiectomy confers 10-fold higher odds of recurrence. Two-year recurrence-free survival was 89% when plasma levels were undetectable within 6 weeks post-orchiectomy versus only 32% with detectable levels (Medscape 2026).
• DigiMir Pipeline (ddPCR): Droplet digital PCR-based detection achieved 94% sensitivity and 100% specificity, outperforming the combined sensitivity of all three classical serum markers (61.5%).
• S1STeM 371 Trial: Clinical evaluation of miR-371a-3p in small testicular masses is ongoing, potentially expanding the biomarker's role in pre-operative decision-making.

• Superior alternative exists: miR-371a-3p provides better sensitivity and specificity for disease monitoring
• Lower detection rates: ctDNA detected in only 30-60% of cases vs 88-98% for miR-371a-3p
• Excellent standard therapy: BEP chemotherapy achieves cure in >95% of patients, limiting need for molecular profiling
• Few therapeutic implications: Limited actionable mutations with available targeted therapies
• Emerging application only: ctDNA remains investigational while miR-371a-3p has established clinical utility

Tumor-Informed ctDNA MRD Detection (ASCO GU 2024, JCO 2024;42(4 suppl):499 and JCO 2024;42(16 suppl):5034): Two landmark studies presented at the ASCO Genitourinary Cancers Symposium and ASCO Annual Meeting 2024 demonstrated the potential of bespoke tumor-informed ctDNA (Signatera) in testicular cancer:

• Detection Rate: Pre-orchiectomy ctDNA detected in 91.6% (11/12) of stage I and 100% of stage II/III patients
• Post-Orchiectomy Clearance: ctDNA clearance achieved in 80% of patients
• MRD Window Prediction: Patients with undetectable MRD ctDNA had superior 3-month (100% vs 25%) and 12-month event-free survival (91% vs 13%) compared to detectable ctDNA
• Multivariate Analysis: Any-time ctDNA-positivity during surveillance was the only factor significantly associated with poor event-free survival, outperforming clinicopathological features
• High NPV: Undetectable MRD window ctDNA demonstrated high negative predictive value relative to imaging studies in clinical stage I disease
• Sample Size: 145 plasma samples from 35 patients (stages I-III) with personalized mPCR-NGS assay

Published Validation (JCO Precis Oncol 2025): The longitudinal ctDNA evaluation was published as a full paper, confirming that tumor-informed ctDNA analysis shows promise for MRD detection in testicular cancer. With further validation, ctDNA monitoring may have clinical utility in treatment decision-making, particularly for clinical stage I surveillance strategies where the key question is whether to pursue active surveillance or adjuvant therapy.

Key Takeaways: Testicular Cancer Liquid Biopsy

• miR-371a-3p is the primary liquid biopsy biomarker: 88-98% sensitivity and 92-100% specificity for active disease, substantially superior to both conventional markers (~50% sensitivity) and ctDNA (30-60% detection)
• Critical advantage for marker-negative disease: Enables monitoring of seminomas and pure embryonal carcinoma where conventional markers are typically negative
• Early relapse detection: miR-371a-3p detects recurrence earlier than conventional imaging modalities
• ctDNA emerging role: ASCO 2024 data shows tumor-informed ctDNA detects 91.6% of stage I tumors pre-orchiectomy; MRD-positive patients have significantly inferior event-free survival (12-month EFS 13% vs 91% for MRD-negative)
• Excellent prognosis: >95% cure rate with standard BEP chemotherapy reduces need for extensive molecular profiling
• miR-371 regulatory progress: FDA Breakthrough Device Designation (March 2025) for mir|detect assay; 10-fold recurrence risk with detectable miR-371 post-orchiectomy
• Future directions: ctDNA under investigation for platinum-refractory disease and clinical stage I surveillance decision-making; multi-analyte approaches combining cfDNA with N-glycan analysis emerging